- Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
-
Kim DY, Nam J, Chung Js, Kim SW, Shin HJ
- KMID: 2524611
- Cancer Res Treat.
- 2022 Jan;54(1):301-313.
- doi: 10.4143/crt.2020.1371
Purpose There are unmet needs associated with the current treatment strategies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due to the poor treatment outcomes of these strategies. Roflumilast, a selective... -
- CITED
-
- Close
- SHARE
-
- Close
- Genomics of diffuse large B cell lymphoma
-
Koh Y
- KMID: 2515302
- Blood Res.
- 2021 Apr;56(S1):S75-S79.
- doi: 10.5045/br.2021.2021049
Next generation sequencing (NGS) technology has revealed the heterogeneity of diffuse large B-cell lymphoma (DLBCL) from a mutation perspective. Accordingly, the conventional cell of origin-based classification of DLBCL has changed... -
- CITED
-
- Close
- SHARE
-
- Close
- Curcumin Inhibits the Proliferation, Migration, Invasion, and Apoptosis of Diffuse Large B-Cell Lymphoma Cell Line by Regulating MiR-21/VHL Axis
-
Chen L, Zhan CZ, Wang T, You H, Yao R
- KMID: 2466332
- Yonsei Med J.
- 2020 Jan;61(1):20-29.
- doi: 10.3349/ymj.2020.61.1.20
PURPOSE: Curcumin exerts its anti-cancer effects, partly by targeting special microRNAs, in human cancers. MiR-21 is a key oncomir in carcinogenesis of multiple human cancers. Here, we aimed to further... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
-
Kim DY, Song MK, Chung JS, Shin HJ, Yang DH, Lim SN, Oh SY
- KMID: 2466589
- Blood Res.
- 2019 Dec;54(4):244-252.
- doi: 10.5045/br.2019.54.4.244
BACKGROUND: Systemic inflammatory response can be associated with the prognosis of diffuse large B cell lymphoma (DLBCL). We investigated the systemic factors significantly related to clinical outcome in relapsed/refractory DLBCL. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical significance of cell-free DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma
-
Eskandari , Manoochehrabadi S, Pashaiefar H, Zaimy MA, Ahmadvand
- KMID: 2451011
- Blood Res.
- 2019 Jun;54(2):114-119.
- doi: 10.5045/br.2019.54.2.114
BACKGROUND: Cell-free DNA (cfDNA) has the potential to serve as a non-invasive prognostic biomarker in some types of neoplasia. The investigation of plasma concentration of cfDNA may reveal its use... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Significance of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
-
Park LC, Lee HS, Lee EM, Shin SH, Kim YS
- KMID: 2365237
- Kosin Med J.
- 2016 Dec;31(2):122-133.
- doi: 10.7180/kmj.2016.31.2.122
OBJECTIVES: The both values of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) were reported as indexes of systemic inflammation and readily available and inexpensive prognostic markers in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Utility Analysis for Pegfilgrastim in DLBCL Patients on R-CHOP Regimen
-
Jung HW, Kim JM, Min MS, Lee YM, Bang JS
- KMID: 2226406
- Korean J Clin Pharm.
- 2015 Sep;25(3):151-158.
- doi: 10.0000/kjcp.2015.25.3.151
OBJECTIVE: This study was designed to compare pegfilgrastim and filgrastim in diffuse large B-cell lymphoma (DLBCL) patients treated with a rituximab with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (R-CHOP) regimen in... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
-
Oh S, Koo DH, Suh C, Kim S, Park BH, Kang J, Huh J
- KMID: 1786010
- J Korean Med Sci.
- 2011 Dec;26(12):1556-1562.
- doi: 10.3346/jkms.2011.26.12.1556
Many predictive models have been proposed for better stratification of diffuse large B-cell lymphoma (DLBCL). Hans' algorithm has been widely used as standard to sub-classify DLBCL into germinal center B-cell... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B cell lymphoma treated with R-CHOP
-
Kim SN, Chae YS, Kim JG, Moon JH, Lee SJ, Kim YJ, Lee YJ, Sohn SK
- KMID: 2257387
- Korean J Med.
- 2009 Jan;76(1):52-59.
BACKGROUND/AIMS: The International Prognostic Index (IPI) and absolute lymphocyte count (ALC) are prognostic factors in diffuse large B cell lymphoma (DLBCL). Nevertheless, in the Rituximab era, a new predictive marker... -
- CITED
-
- Close
- SHARE
-
- Close
- Rituximab and ESHAP as Second-line Therapy for Relapsed or Primary Refractory Diffuse Large B Cell Lymphoma: The Experience of a Single Center in Korea
-
Ko OB, Kim S, Lee DH, Kim SW, Huh J, Suh C
- KMID: 2252215
- Korean J Hematol.
- 2007 Dec;42(4):309-316.
- doi: 10.5045/kjh.2007.42.4.309
BACKGROUND: The remission status prior to autologous stem cell transplantation (ASCT) influences the transplantation outcome in patients with relapsed or primary refractory diffuse large B cell lymphoma (DLBCL), a complete... -
- CITED
-
- Close
- SHARE
-
- Close
